Agios Pharmaceuticals Inc
AGIO
$30.21
Closing
▲2.30%
1D
▲35.65%
YTD
Market cap
$1.70B
52 week high
$35.48
52 week low
$19.81
Volume
286,458
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$1.70B
Analysts' Rating
BUY
Price Target (Mean)
38
Total Analysts
8
P/E
Operating Margin
-1363.66%
Beta
0.82
Revenue Growth (Annual)
0.00%
52 week high
$35.48
52 week low
$19.81
Div. Yield
%
EPS Annual Growth
8.61
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.
